188 related articles for article (PubMed ID: 11495074)
21. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors.
Katz PO; Anderson C; Khoury R; Castell DO
Aliment Pharmacol Ther; 1998 Dec; 12(12):1231-4. PubMed ID: 9882031
[TBL] [Abstract][Full Text] [Related]
22. Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain.
Xia HH; Lai KC; Lam SK; Hu WH; Wong NY; Hui WM; Lau CP; Chen WH; Chan CK; Wong WM; Wong BC
Aliment Pharmacol Ther; 2003 Feb; 17(3):369-77. PubMed ID: 12562449
[TBL] [Abstract][Full Text] [Related]
23. Review article: long-term use of proton pump inhibitors in GORD--help or hindrance?
Tytgat GN
Aliment Pharmacol Ther; 2001 Sep; 15 Suppl 2():6-9. PubMed ID: 11556874
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease.
Castell D; Bagin R; Goldlust B; Major J; Hepburn B
Aliment Pharmacol Ther; 2005 Jun; 21(12):1467-74. PubMed ID: 15948814
[TBL] [Abstract][Full Text] [Related]
25. Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-centre study.
Fass R; Murthy U; Hayden CW; Malagon IB; Pulliam G; Wendel C; Kovacs TO
Aliment Pharmacol Ther; 2000 Dec; 14(12):1595-603. PubMed ID: 11121907
[TBL] [Abstract][Full Text] [Related]
26. One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease.
Johnsson F; Weywadt L; Solhaug JH; Hernqvist H; Bengtsson L
Scand J Gastroenterol; 1998 Jan; 33(1):15-20. PubMed ID: 9489902
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK.
Remák E; Brown RE; Yuen C; Robinson A
Curr Med Res Opin; 2005 Oct; 21(10):1505-17. PubMed ID: 16238890
[TBL] [Abstract][Full Text] [Related]
28. Rabeprazole: an update of its use in acid-related disorders.
Carswell CI; Goa KL
Drugs; 2001; 61(15):2327-56. PubMed ID: 11772142
[TBL] [Abstract][Full Text] [Related]
29. Esomeprazole: a review of its use in the management of acid-related disorders in the US.
Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
Drugs; 2002; 62(7):1091-118. PubMed ID: 11985491
[TBL] [Abstract][Full Text] [Related]
30. Pantoprazole 20 mg is an effective maintenance therapy for patients with gastro-oesophageal reflux disease.
Plein K; Hotz J; Wurzer H; Fumagalli I; Lühmann R; Schneider A
Eur J Gastroenterol Hepatol; 2000 Apr; 12(4):425-32. PubMed ID: 10783996
[TBL] [Abstract][Full Text] [Related]
31. Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole.
Adachi K; Hashimoto T; Komazawa Y; Mihara T; Furuta K; Fujishiro H; Ishihara S; Amano Y; Hattori S; Kinoshita Y
Dig Liver Dis; 2005 Jul; 37(7):485-90. PubMed ID: 15975534
[TBL] [Abstract][Full Text] [Related]
32. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Röhss K; Lind T; Wilder-Smith C
Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
[TBL] [Abstract][Full Text] [Related]
33. One-week esomeprazole treatment: an effective confirmatory test in patients with suspected gastroesophageal reflux disease.
Johnsson F; Hatlebakk JG; Klintenberg AC; Román J; Toth E; Stubberöd A; Falk A; Edin R
Scand J Gastroenterol; 2003 Apr; 38(4):354-9. PubMed ID: 12739706
[TBL] [Abstract][Full Text] [Related]
34. Managing gastro-oesophageal reflux disease in children.
Cezard JP
Digestion; 2004; 69 Suppl 1():3-8. PubMed ID: 15001829
[TBL] [Abstract][Full Text] [Related]
35. Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study.
Dent J; Vakil N; Jones R; Bytzer P; Schöning U; Halling K; Junghard O; Lind T
Gut; 2010 Jun; 59(6):714-21. PubMed ID: 20551454
[TBL] [Abstract][Full Text] [Related]
36. Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis.
Richter JE; Kovacs TO; Greski-Rose PA; Huang section sign B; Fisher R
Aliment Pharmacol Ther; 1999 Jun; 13(6):795-804. PubMed ID: 10383510
[TBL] [Abstract][Full Text] [Related]
37. Ninety-six-hour wireless oesophageal pH monitoring following proton pump inhibitor administration in NERD patients.
Calabrese C; Liguori G; Gabusi V; Gionchetti P; Rizzello F; Straforini G; Brugnera R; Di Febo G
Aliment Pharmacol Ther; 2008 Jul; 28(2):250-5. PubMed ID: 18485128
[TBL] [Abstract][Full Text] [Related]
38. Endoscopic gastroplication for the treatment of gastro-oesophageal reflux disease: a randomised, sham-controlled trial.
Schwartz MP; Wellink H; Gooszen HG; Conchillo JM; Samsom M; Smout AJ
Gut; 2007 Jan; 56(1):20-8. PubMed ID: 16763053
[TBL] [Abstract][Full Text] [Related]
39. Proton pump inhibitors or surgery for gastro-oesophageal reflux disease.
Hinder RA
Dig Liver Dis; 2002 Feb; 34(2):95-6. PubMed ID: 11926565
[No Abstract] [Full Text] [Related]
40. Improving health-related quality of life in gastro-oesophageal reflux disease.
Shaw MJ; Crawley JA
Drugs; 2003; 63(21):2307-16. PubMed ID: 14524732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
